Konan Medical’s EyeKinetix Pupillograph is Now Available in the United States
Konan Medical announced that EyeKinetix is FDA listed and now available for sale in the United States.
EyeKinetix is Konan’s 2nd generation pupillograph, which is smaller, faster, easier to use and less expensive than its predecessor, RAPDx, a device that brought key pupillary testing advancements, according to a company news release.
EyeKinetix features the RAPDx objective, automated test to assess Relative Afferent Pupillary Defects in less than 1 minute. RAPD measures have historically been performed manually with a swinging flashlight method generally regarded as being difficult for clinicians to do well. The device will also measure high- and low-light pupil sizes which may be useful to physicians in planning for multifocal IOLs, contact lenses, and refractive surgery implications and is designed for the company to add additional testing features over time. EyeKinetix is delivered with Konan’s proprietary precision color and luminance calibration system on a tablet/PC with a free 90-day trial of ColorDx CCT HD, Konan’s color vision diagnostics test. CCT HD was designed with the US Air Force school of Aerospace Medicine and OBVA team.
“The RAPDx score provides a highly sensitive and specific assessment of the RAPD as tested by the swinging flashlight method,” Nicholas Volpe, MD, Chair, Department of Ophthalmology, George W. and Edwina S. Tarry Professor of Ophthalmology at Northwestern Medicine’s Feinberg School of Medicine in Chicago, said in the news release. “It is easily used by ancillary personnel as part of the screening of patients and is a powerful tool for clinicians needing to identify, confirm and quantify relative afferent pupillary defects.”
Examining pupils for RAPDs is recommended in several of the American Academy of Ophthalmology’s Preferred Practice Patterns for adult eye exams and open angle glaucoma and is recommended by the American Optometric Association in several Clinical Practice Guidelines including pediatric and adult comprehensive eye exam and open angle glaucoma.
“There has been significant anticipation of this product and we are really excited to bring this new technology to market,” Ian McMillan, Vice President of North American Sales and Marketing at Konan Medical, said in the news release. “EyeKinetix, with the RAPDx test, is already viewed by the ophthalmic community as a quick, affordable, objective solution for one of few procedures left that are not performed using a diagnostic ophthalmic device.”
“EyeKinetix is a collaboration with UT Dallas School of Biomedical Engineering and represents the best aspects of our first generation pupillograph with innovative engineering from the UT Dallas team,” Charles Wm. Stewart, OD, CEO of Konan Medical USA, said in the news release. “There has been considerable effort placed in enhanced value, precision, lower price-points, but with clear pathways to add-in software-driven features for the product.”